.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope you're right! Maybe we'll get some more news tomorrow! :)
Thanks for your input. The company has some fairly big potential, in my opinion. Hopefully the name change that takes place next week will move it up a bit as well.
GLTA!
LOL. Thanks!
GLTA.
Sounds great... I've watched IDGI for a while, but since I had Scottrade, I couldn't purchase it. But I've recently switched to E*Trade, so I can purchase it now.
GLTA!
$1 will be seen in 3-4 weeks, imo...
JMO, don't invest based on my opinion!
GLTA!
Ugh.... Crappy close today. Anyone think we'll see .005 again?
GLTA.
Hey DanSZ,
What price do you think we're looking at after the unveiling in a few days? I've got a spare hundred bucks and am thinking about putting it here in IDGI...
GLTA!
Higher lows...
GLTA!
Sounds great! Think we'll see .01 by Friday?
GLTA!
I agree with you... The PRs from yesterday and today are HUGE, imo!
JMO.
GLTA!
Just got some shares @ .15!
GLTA!
Looks great, imo!
GLTA!
According to pinksheets it's under 500 million...
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=IVOT#getCompanyInfo
Just bought a small position, let's see what happens!
GLTA!
Hey George, any thoughts on what PPS we could see after the presentation of data?
Hey Chart, do you still think HCEI is going over $1?
Thanks.
Closed at HOD @ $1.09
GLTA!
NITE on ask @ 1.09...
Looking good today!
GLTA!
Letter to Shareholders from 2009 Annual Report:
Dear Shareholders, Employees, Colleagues and Friends,
On 9 September 2009 ChemGenex announced the submission of its New Drug Application (NDA) for OMAPRO™
(omacetaxine mepesuccinate) to the US Food and Drug Administration (FDA). This major achievement capped an
outstanding year for the company that has seen it become recognized internationally as an innovator and leader in the
field of hematology therapeutic research and development.
With this submission to the FDA, and a planned parallel submission to the European Medicines Agency (EMEA) due in
Q4 2009, ChemGenex is on the threshold of drug approvals in the two major global therapeutic markets, and is well
positioned to deliver on our goal of improving patient outcomes and shareholder value.
These initial regulatory submissions describe the use of OMAPRO™ in chronic myelogeneous leukemia (CML) patients
who have failed therapy with the tyrosine kinase inhibitor, imatinib, and who have a particular gene mutation, the T315I
mutation, which renders them resistant to all approved CML therapies. Data from the clinical trial in this patient group
have been delivered as oral presentations at several international congresses over the past year, and the response from physicians and patient support groups has been very encouraging. In addition to the pivotal clinical trial in CML patients with the T315I mutation ChemGenex is conducting a complementary clinical study of OMAPRO™ in CML patients who have failed multiple tyrosine kinase inhibitors (regardless of their
mutation status). Data from this study have also been very encouraging, and may be used in future regulatory submissions.
Certainly it is ChemGenex’s belief that OMAPRO™ may provide new hope for CML patients who have failed treatment
with multiple tyrosine kinase inhibitors.
While CML is the short term focus for the development of OMAPRO™, our increasing understanding of the novel
mechanism of action of the drug supports its development more broadly in other hematologic cancers. ChemGenex has
an ongoing phase 2 study of OMAPRO™ in refractory or relapsed acute myeloid leukemia (AML) patients who have failed
intensive chemotherapy and we are also exploring further development opportunities in a range of other hematological
disorders.
The coming year could see the realization of years of effort, with the possible commercial launch of OMAPRO™ in mid
2010. Key milestones in the next 12 to 18 months could include:
* Completion of our first regulatory filings for OMAPRO™ in Europe
* Establishment of a partnership for the commercialization of OMAPRO™ in Europe
* Completion of the phase 2/3 trial of OMAPRO™ in CML patients who have failed multiple tyrosine kinase inhibitors
* Presentation of final clinical data from the T315I+ CML clinical trial at leading international conferences
* Possible approval and commercial launch of OMAPRO™ in the USA
We appreciate your continued support for ChemGenex and look forward to communicating with you during the exciting
year ahead.
Brett Heading
Chairman
Greg Collier
CEO and MD
Link to 2009 Annual Report w/ above letter: http://www.chemgenex.com/pdf/Annual_Report_2009_Final.pdf
GLTA.
ChemGenex CEO Receives AusBiotech Award
MELBOURNE, Australia, and MENLO PARK, California U.S.A.
October 28, 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) is pleased to announce Chief Executive Officer and Managing Director Greg Collier, PhD. was recognized this morning for his outstanding contribution to the advancement of biotechnology in Australia.
Dr Collier received the AusBiotech 2009 Chairman’s Excellence Award for outstanding contribution by an individual within a company. The Board and management of ChemGenex extend their congratulations to Dr Collier upon the receipt of this award.
About ChemGenex Pharmaceuticals Limited (http://www.chemgenex.com)
ChemGenex is an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The company is developing its lead product candidate OMAPRO™ (formerly omacetaxine) for the treatment of patients with Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). A New Drug Application has been submitted to the U.S. Food and Drug Administration for CML patients with the Bcr-Abl T315I mutation. The corporate strategy for ChemGenex is to commercialize OMAPRO™ independently in North America and to establish commercial partnerships in the rest of the world. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS". For additional information on ChemGenex Pharmaceuticals, please visit the company’s website at http://www.chemgenex.com.
Details on the clinical trials can be accessed from the following websites; http://clinicaltrials.gov/ct2/show/NCT00375219?term=homoharringtonine&rank=9 and http://www.tkiresistantcmltrials.com
ChemGenex Submits New Drug Application for OMAPRO™ (Omacetaxine Mepesuccinate) to U.S. FDA
MELBOURNE, Australia, and MENLO PARK, California U.S.A.
September 09, 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. Imatinib, a tyrosine kinase inhibitor (TKI), is the first-line standard of care for patients with CML. OMAPRO™ is a first-in-class cetaxine which works differently from imatinib, and the second-line TKIs nilotinib and dasatinib.
OMAPRO™ has received Orphan Drug designation in the U.S. and in the European Union, and has received fast track status from the FDA. OMAPRO™ demonstrated clinical benefit in the pivotal Study 202, in CML patients who had failed imatinib and have the T315I mutation. Interim data were recently presented at the American Society of Clinical Oncology Annual Meeting.
“If approved, OMAPRO™ would be the first treatment specifically indicated for CML T315I patients, many of whom have no therapeutic options,” said Adam R. Craig MD, PhD, Senior Vice President and Chief Medical Officer. “We thank the investigators, their research staff and patients for participating in the pivotal study.”
If the FDA grants priority review for OMAPRO™ the examination period is expected to be approximately six months. If approved for marketing by the FDA following priority review, the launch of OMAPRO™ would be scheduled for mid-2010.
Greg Collier PhD, ChemGenex’s Chief Executive Officer and Managing Director, said, "The submission of the NDA for OMAPRO™ is a major milestone in the development of this novel product and we are now one step closer to delivering a new treatment for patients in an area of unmet medical need. This submission is a significant achievement in our strategic goal to commercialize OMAPRO™ independently in the U.S. oncology market.”
About Chronic Myeloid Leukemia (CML) and the Bcr-Abl T315I Mutation
Chronic myeloid leukemia (CML) is a cancer of the bone marrow with a worldwide prevalence of approximately 200,000 patients. The bone marrow is responsible for the production of specialized cells that constitute blood; these cells include red blood cells (to carry oxygen around the body), thrombocytes (to help stop bleeding) and certain white cells (part of the body’s defense system against infection). In patients with CML the cell production system is diseased and defective. Cells multiply uncontrollably and do not fully develop (differentiate) into functional blood cells.
The majority of newly diagnosed CML patients initially respond well to treatments with drugs called tyrosine kinase inhibitors (TKIs). However, a significant proportion of patients fail or become intolerant to one or more TKIs. In many of these situations the cause of failure can be traced to the emergence of Bcr-Abl mutations. A common mutation called T315I renders CML resistant to all currently approved TKIs, and has created a significant unmet medical need in the management of CML.
About OMAPRO™ (omacetaxine mepesuccinate)
Omacetaxine is administered subcutaneously and acts differently from TKIs. It may have a therapeutic advantage for patients who have failed TKIs. Omacetaxine is currently in global phase 2/3 clinical trials for CML and has been granted Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMEA) as well as Fast Track status by the FDA.
Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, specifically binding to the ribosomal A-site cleft and inhibiting protein translation of short-lived oncoproteins that are upregulated in leukemic cells (particularly Cyclin-D1, Mcl-1 and c-Myc). In addition, pre-clinical research presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany this summer, demonstrated that omacetaxine kills human CML stem cells that are known to be insensitive to TKIs.
About ChemGenex Pharmaceuticals Limited
ChemGenex is an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The company is developing omacetaxine, its lead product candidate, for the treatment of patients with Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). A New Drug Application has been submitted to the U.S. Food and Drug Administration for CML patients with the Bcr-Abl T315I mutation. The corporate strategy for ChemGenex is to commercialize omacetaxine independently in North America and to establish commercial partnerships in the rest of the world. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" For additional information on ChemGenex Pharmaceuticals, please visit the company’s website at http://www.chemgenex.com.
Details on the clinical trials can be accessed from the following websites:
http://www.clinicaltrials.gov/ct2/show/NCT00375219?term=homoharringtonine&rank=9 and http://www.tkiresistantcmltrials.com
OMAPRO™ is a trademark of ChemGenex Pharmaceuticals Limited
For more information on the company and afamelanotide: www.clinuvel.com
GLTA.
Clinuvel Pharma: Three Prospective Game-Changing Events in Three Months -- http://seekingalpha.com/instablog/441189-mike-rabe/32145-clinuvel-pharma-three-prospective-game-changing-events-in-three-months
Clinuvel Pharmaceuticals (CUV.AX, CLVLY.OTC) is expecting to report on key binary events in the coming months – and as of right now, these binary events are flying under the radar in the biotech investing world. This presents an intriguing opportunity for those investors who are looking for a high risk / high potential reward play in biotech.
These events will be game changers – and they are all right around the corner. Let’s preview them:
1. Results from the Phase III EPP trial –
Clinuvel is banking on solid Phase III EPP (porphyria – absolute sun/UV intolerance) results from the current trials in Europe and Australia. The EPP trial is their lead trial for their first-in-class photoprotective drug, afamelanotide. Results are expected in within three months. Positive results will significantly de-risk the Company and should spawn several more accomplishments soon, such as trials in the US and a trade name for afamelanotide.
Note that in January 2009, the Company reported positive interim Phase III results for EPP.
2. Interim results from the Phase III PLE trial –
The PLE (polymorphic light eruption – sun/UV poisoning) indication for afamelanotide holds the largest potential on-label market for the drug. I’m personally putting more weight on the results of this trial than others are. If the PLE trial does not meet its primary endpoint, I would consider this a pretty big blow to the Company. Given there are a handful of clinical indications for afamelanotide, disappointing PLE results would not be deadly, but would certainly have a negative effect on shareholders.
Interim PLE results are expected in Q4 2009.
3. FDA Green Light for a USA Phase III trial –
It appears the Company is waiting for the FDA to grant clearance for a confirmatory Phase III EPP trial. Approval of this trial would be a watershed event for the Company for a couple reasons:
First, the Company would finally be on path to starting a major trial for afamelanotide on American soil, roughly 20 years after the synthetic version of the melanocyte stimulating hormone was first created by researchers at the University of Arizona.
Second, it is extremely rare for any Australian biotech company to achieve late-stage drug trial status with the FDA. The Company would be on path to entering the largest pharmaceutical market.
Clinuvel is hoping to begin a Phase III EPP confirmatory trial in Q2 2010.
*******
One thing is for certain – Clinuvel Pharmaceuticals is about to enter the most important 3-4 month period of its history. The above-mentioned binary events will determine much of the Company’s fate.
Disclosure: Long Clinuvel
Themes: Clinuvel, biotech, pharmaceuticals Stocks: CLVLY.PK
PuraMed BioScience, Inc. to Launch E-Commerce Website for Online Purchases of Its Non-Prescription Migraine Treatment LipiGesic(TM) M
Wednesday 11/04/2009 9:02 AM ET - Globenewswire
PuraMed BioScience (OTCBB:PMBS), announced today it has accelerated the construction of its e-commerce website due to the volume of calls coming into PuraMed's headquarters inquiring when the Company's migraine headache treatment LipiGesic(TM) M, will become available for purchase. The site is expected to launch mid November 2009 and will include innovative brand images and messages with fully functional e-commerce capability. The site can be found at www.LipiGesic.com. The company will also promote several URLs that will redirect to the main LipiGesic.com website, including the vanity site www.mymigrainegone.com and www.LipiGesicM.com.
Russ Mitchell, PuraMed BioScience President and CEO stated, "We have been working diligently to complete production of our first direct response television commercial and our e-commerce offering. As we continue to finalize production and identify the best airing times available for our commercial, we believe that providing this e-commerce site will allow us to help migraine sufferers who have already heard about the product and help others discover a new, more effective and affordable option to alleviate their migraine pain."
Mitchell continued, "LipiGesic.com will be the 'online storefront' and visual representation of our products for consumers, and also a main resource for information on migraine headaches. We believe our new website will greatly support our efforts and begin generating revenue as we move ahead with developments for the launch of our products."
About the Company:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic(TM) M, which provides acute relief from migraine headaches; the Company also has plans to launch LipiGesic(TM) PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic(TM) H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: PuraMed BioScience
CONTACT: PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
Website: www.PuramedBioScience.com
Investor Awareness, Inc.
Investor Relations:
Tony Schor
James Foy
847-945-2222
Website: www.investorawareness.com
North Shore Public Relations, Inc.
Media Contact:
Renae Placinski
847-945-4505
Renae@northshorepr.com
Website: www.northshorepr.com
Just bought in @ .06... Had some a while back at .02 but got impatient and sold out... Looks like everything is finally coming together, imo.
GLTA!
Conf. Call went very well imo.
Transcript of CC: http://seekingalpha.com/article/170675-chelsea-therapeutics-international-ltd-q3-2009-earnings-call-transcript
GLTA!
Chelsea Therapeutics Reports Third Quarter 2009 Results -- http://finance.yahoo.com/news/Chelsea-Therapeutics-Reports-pz-3420828839.html?x=0&.v=1
Been watching this... Looks promising, imo.
GLTA!
Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate. ExcellagenXL is an advanced wound care management medical device, which is a customized collagen-based topical gel designed for use by physicians in patients with topical wounds, which include diabetic ulcers as well as pressure ulcers, venous ulcers, surgical and trauma wounds, second degree burns, and other types of wounds. The Company expects to submit its FDA 510(k) application for ExcellagenXL during the current quarter.
The planned 510(k) filing is based in part on positive findings from the Company's Phase 2b Matrix clinical study, reported October 14, 2009, indicating that substantial improvements in wound healing responses were observed in patients with non-healing diabetic foot ulcers following one or two applications of ExcellagenXL. The ExcellagenXL topical gel wound care product is designed to promote a favorable environment for effective wound management by providing a moist protective barrier as well as a micro-scaffold that promotes cell migration and capillary in-growth.
ExcellagenXL is an advanced wound care device composed of highly-refined, soluble bovine dermal collagen (Type I), which is modified to reduce immunogenicity and promote its usefulness in wound settings. ExcellagenXL is planned for physician use in conjunction with standard of care wound therapy, which in the case of diabetic ulcers typically includes surgical debridement and off-loading. ExcellagenXL is expected to be indicated for use at two-week intervals (with weekly outer dressing changes) as an adjunct to surgical debridement, and supplied in a sterile single-use syringe along with a sterile flexible application needle to facilitate topical administration over the wound site. ExcellagenXL will be stored at standard refrigeration temperature (2 degrees C - 8 degrees C).
Cardium also announced plans to develop additional new product opportunities by incorporating other agents into Excellagen formulations, including antimicrobials, DNA and/or other biologics, which are designed to address particular wound healing and other tissue repair applications.
"We are pleased to announce plans to submit our FDA 510(k) premarket notification of our ExcellagenXL collagen-based topical gel. The 510(k) clearance process provides us with a potential near-term opportunity to introduce this product into the rapidly-growing market for advanced wound care. Applying our specialized formulation know-how and the unique properties of our collagen-based matrix technology, we also look forward to introducing additional Excellagen-based products in the near future," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that Excellagen, Excellarate or our other candidates will prove to be sufficiently safe and effective, or that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the Excellagen or Excellarate product candidate offers the potential for simpler or more cost-effective treatment for physicians and patients than other FDA-approved products that currently are or will be on the market; that the Matrix clinical study program or other human clinical trials can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2009 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.
Cardium Therapeutics(TM) and Generx® are trademarks of Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM) and Osteorate(TM) are trademarks of Tissue Repair Company.
If this holds up, looks like we'll close just over $1...
GLTA!
Yeah, I agree. Hasn't Nuvo received a CRL at least two times? Volume will remain low until approval/rejection/CRL, imo.
GLTA.
A lot of biotechs/pharmas have low volume until big news hits, OPXA is a good example.
GLTA!
Two more days... :D
GLTA!
Chelsea Therapeutics Appoints Dr. William D. Schwieterman Chief Medical Officer
CHARLOTTE, N.C, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP - News) announced the appointment of William D. Schwieterman, M.D., to the newly created position of Chief Medical Officer. Dr. Schwieterman, who resigned his seat on Chelsea's Board of Directors to assume the position, will be responsible for medical and regulatory affairs, and will report to Simon Pedder, Ph.D., Chelsea's President and Chief Executive Officer.
"Bill joins Chelsea's management team at a time when his experience will be invaluable across each of our clinical programs," said Dr. Simon Pedder. "Having known Bill for 12 years, going back to the development of Pegasys(R), I was delighted to first welcome his insight and expertise on our rheumatology scientific advisory board and later on the Company's Board of Directors. Given the extensive regulatory experience he gained during his 10 year tenure at the FDA, his deep knowledge of Chelsea, and commitment to our therapeutic pipeline, we believe Bill's contributions as Chief Medical Officer will be instrumental as we work toward approval of Droxidopa in neurogenic orthostatic hypotension and continue to advance all of our product candidates."
Dr. Schwieterman, a rheumatologist and board-certified internist, brings over 25 years of experience to Chelsea with a career spanning medical practice, drug development, and regulatory oversight. For the past year, Dr. Schwieterman held a seat on Chelsea's Board of Directors following three years of service on the Company's rheumatology advisory board. While advising Chelsea, he also served as an independent consultant to other biotechnology and pharmaceutical companies, focusing on clinical development and regulatory matters since 2002. Prior to that, Dr. Schwieterman was Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, he worked with sponsors for the development of new agents for pulmonary medicine, neurology, hepatitis, rheumatology, infectious disease, and solid organ transplantation, among other areas.
In addition to having helped author the FDA's Good Review Practices for investigational products, Dr. Schwieterman is widely published in peer-reviewed journals. Dr. Schwieterman received his M.D. from the University of Cincinnati and his internship and residency programs were completed at Mt. Sinai Hospital in New York City. Dr. Schwieterman's research training was obtained at the National Institutes of Health in Bethesda, Maryland. He currently serves on the board of directors and compensation committee of OXiGENE, Inc., a publicly traded company.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.
Holds up well here @ $2.30... Not much volume though...
GLTA!
If MSBT gets positive news, we could be looking at HGSI #2, imo.
GLTA!
Earnings will be out today, as well as an update on ANA-598.
From PR:
Anadys will hold a conference call and webcast on Thursday, October 29, 2009 at 5:00 p.m. Eastern Daylight Time to discuss its third quarter 2009 financial results and highlights and to provide an update on the ANA598 program
No problem!
GLTA!
Hopefully we'll get a PR update soon -- next week would be great for one, imo.
Nice find on the Lipigesic website. Getting closer and closer to launch, imo.
GLTA!
So is my purchase at .13! :)
GO WAMUQ!!!